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Abstract 
 
Societies worldwide are investing considerable resources into the safe development and use of 
nanomaterials. Whilst each of these protective efforts are crucial for governing the risks of 
nanomaterials, they are insufficient in isolation. What is missing is a more integrative 
governance approach that goes beyond legislation. Development of this approach must be 
evidence-based and involve key stakeholders to ensure acceptance by end users. The 
challenge is to develop a framework that coordinates the variety of actors involved in 
nanotechnology and civil society to facilitate consideration of the complex issues that occur in 
this rapidly evolving research and development area. Here, we propose three sets of essential 
elements required to generate an effective risk governance framework for nanomaterials: 
1. Advanced tools to facilitate risk-based decision-making, including an assessment of the 
needs of users regarding risk assessment, mitigation and transfer. 2. An integrated model of 
predicted human behavior and decision-making concerning nanomaterial risks. 3. Legal and 
other (nano-specific and general) regulatory requirements to ensure compliance and to 
stimulate proactive approaches to safety. The implementation of such an approach should 
facilitate and motivate good practice for the various stakeholders to allow the safe and 
sustainable future development of nanotechnology.  
 
Keywords: Decision-making; Nano-regulation; Risk communication; Risk governance; Risk 
management 
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1. INTRODUCTION 
For over a decade it has been recognized that nanotechnologies offer great opportunities for 
society, but for them to reach their full potential the risks, particularly of nanomaterials 
(NMs), must be addressed.
(1)
 An ever-expanding heterogeneous array of NMs are being 
incorporated into a diverse range of industries and applications. This variety and wide-spread 
use has fostered a growing interest in their safety and risk management. Thus, key 
stakeholders worldwide invest considerable resources into the safe development and use of 
NMs. More specifically, governments, private companies, and other actors have sought to 
govern human behaviors and decisions related to NMs through the use of various tools and 
risk management efforts. For example, internationally much effort has been directed to 
support risk assessment/management related research which will both help companies 
implement risk prevention (and mitigation) strategies, as well as aid the development of 
general and specific NM-relevant regulations.
(2) 
This work has included expert bodies (e.g. 
Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR)), 
regulators (e.g. European Food Safety Authority (EFSA) or the US Food and Drug 
Administration (FDA) and Environmental Protection Agency (EPA)), as well as academic 
researchers who have investigated whether existing risk assessment procedures and 
frameworks for conventional chemicals are applicable to NMs. In particular, these studies and 
reports have investigated and identified specific challenges for NMs risk assessment.
(3,4) 
This 
work has been complimented by efforts aimed at fostering dialogue with civil society and the 
general public in order to explore risks and advantages (risk communication), and with 
workers to facilitate a better understanding of risks, thereby aiming to stimulate more 
competent decisions and risk-reducing behavioral changes. 
To align these substantial efforts, a comprehensive evidence-based, optimized, and 
transparent risk governance framework, specifically targeted at NMs, is now needed. Against 
the broad range of governance definitions in the literature,
(5) 
we understand governance as the 
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social and institutional arrangements that systematically influence patterns of behavior. These 
include formal regulations, informal norms of appropriateness and established practical 
routines.     
A coherent NM risk governance framework should address the manifold challenges 
that NMs pose to be addressed in a joined-up, coordinated manner, thereby avoiding piece-
meal solutions to NM risk management. It would support the governance of complex and 
consequential risks in the presence of the specific challenges and uncertainty implied by many 
NMs.
(6)
 
 Such a governance framework needs to be relevant to risk-related behaviors and 
decisions by societal actors throughout the life-cycle of a given NM, whether they are pristine 
materials or incorporated into a product. It would structure decision making and influence 
behaviours at the institutional and individual level, allowing identification of the options 
available to the various actors while understanding constraints such as who is entitled or 
required to make a decision, who is responsible and who is liable. 
(7-9)
 Decisions related to 
NM risks are made within a context of both hard law (formal regulations and statues), soft 
law (non-binding agreements and established good practice) and non-legal social norms and 
expectations (e.g. public blaming and shaming, reputational risks). 
In this paper, we address these issues by drawing upon social sciences, material 
science, legal-regulatory science, and risk-related research
(10)
 to identify and describe 
essential elements of a risk governance framework for NMs. Moreover, we provide an outline 
of the tools needed for such a framework, and how they could be integrated effectively. 
Finally, we highlight the key factors required for the success of such an integrated risk 
governance framework. We believe that the proposed framework provides a basis for a 
comprehensive management of NM-related risks that will help to specify the needs for tool 
development to facilitate risk decision making and thus to foster trust in NM innovation.  
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2. THE NEED FOR A SPECIFIC NANO-RISK FRAMEWORK 
Currently the legal or regulatory requirements for nanotechnologies are spread over a 
fragmented set of regulations that cover general substances (e.g. Registration Evaluation 
Authorisation and Restriction of Chemicals (REACH), Toxic Substances Control Act 
(TSCA)), specific goods containing NMs (e.g. food law, chemical law, cosmetics law or 
pharmaceutical law), or aim to protect specific groups exposed to NMs (e.g. occupational 
health and safety regulation). A recent research roadmap by the European NanoSafety Cluster 
summarizes the current status of such regulations in Europe and the USA
(11)
 and includes a 
number of general, non-nano-specific legal or regulatory procedures and frameworks that are 
applicable to nano-relevant risks.
(12-14) 
With respect to REACH, a number of dedicated studies 
(e.g. RIPON) and a REACH Review in 2012
(15)
 have assessed the suitability of this 
legislation,
(16,17)
 leading to a Commission Communication
(18)
 concluding that NMs “are 
covered by the definition of a “substance” in REACH, even though there is no explicit 
reference to nanomaterials.” According to the European Commission, REACH is hence 
applicable to NMs, making such materials subject to general registration with ECHA. 
However, legally this interpretation is not yet binding; final clarification would only be 
provided through an amendment of REACH or a judgment by the Court of Justice of the 
European Union (CJEU). Likewise, the US FDA reviews risk concerns of NMs within the 
context of the specific legal standards applicable to each type of product under its jurisdiction, 
such as with cosmetics, food additives, etc. This product-focused regulatory assessment 
empowers the FDA to conduct pre- and post-market reviews, and to coordinate with 
established domestic and international counterparts via the Emerging Technologies 
Interagency Policy Coordination Committee. 
This suggests that the governance of risks related to NMs should be considered within 
the context of existing regulatory and legal frameworks. However, although the current 
procedures for risk assessment of conventional chemicals may, in principle, be applicable to 
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 6
NMs,
(3,4) 
much effort has been made to improve this process, not only to ensure that it is NM-
relevant, but also with the future ambition to make the process more efficient and intelligent 
in order to deal with the ever expanding number of NMs (and nano-enabled products). Yet, 
current and future NMs pose a set of specific challenges for risk governance, which may 
require a nano-specific risk governance framework.
(6) 
This demand is driven by multiple 
economic and regulatory factors, including the rapid pace of commercial or near-market 
development of NMs on a global scale. A nano-specific framework could harmonize risk-
based approaches for NM assessment for actors with traditionally diverging risk assessment 
practices, and help indicate and ameliorate gaps in NM hazard, exposure, or effects 
assessment that currently drive the field’s uncertainty with regard to health risks. Without 
such a nano-specific framework, it will be difficult for regulators and industry to resolve 
uncertainties posed by NMs and their unique physical characteristics.  
The cross-border flow of information and the internationalization of markets 
necessitate the development of an international paradigm. The different regulatory regimes, in 
particular different attitudes towards the precautionary principle, suggest that a multi-
stakeholder approach that leverages the development of NM best practices through the 
coordination of effort by industry, government, and other relevant parties, could be most 
promising in developing shared practice that fit the various regulatory environments.   
One of the fundamental challenges for risk governance of NMs is that NMs often 
share few common characteristics besides the nanoscale, and that they can exhibit multiple 
forms and variations over their life-cycles.
(19)
 For example, NMs may undergo changes in 
their physicochemical characteristics, such as agglomeration or de-agglomeration, in certain 
environmental conditions, and this change may have an impact on the toxicity of the 
respective NM.
(6)
 This challenge is further compounded by difficulties in identifying, 
quantifying and discriminating between natural and engineered NMs.
(6)
 Not surprisingly, this 
poses problems for the characterization of properties in toxicological studies, which may lead 
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 7
to diversity in the applied methods and therefore difficulties in comparing findings.
(20)
 
Consequently, any framework for governing NM risks needs to pay attention to this specific 
challenge and foster a viable way for risk assessment, notably for next-generation NMs, that 
efficiently considers potential changes in the physicochemical characteristics of NMs during 
their life cycles and the likely use of incomplete datasets. 
Even for a seemingly “simple” question of the risk assessment process, NMs pose 
particular challenges in comparison to conventional chemicals: no agreement so far has been 
reached on a concept of dose, concentration or metric of NMs in test systems.
(6)
 This renders 
the application of current risk assessment practices difficult. 
As well as complying with existing regulatory and legal frameworks, any risk 
assessment framework needs to be sufficiently flexible or adaptable to align with new 
regulations as they adapt and evolve. Examples of this include considerations of 
environmental, occupational, and food/drug-based regulatory requirements and oversight 
driven within the US by the EPA, the Occupational Safety and Health Administration 
(OSHA), and FDA, 
(13,21,22) 
or in Europe by
 
the European Environment Agency, EU-OSHA or 
the EFSA. 
Above we have addressed challenges relating to risk related research, material science 
and the legal-regulatory environment, but in addition a governance framework will benefit 
from integrating perspectives from other domains, in particular social sciences
(10)
 in order to 
develop practical solutions for the important, urgent and complex risk decisions
(23)
 regarding 
NMs at all societal levels. Such a risk governance framework would significantly contribute 
to the goal of achieving sustainable development for nanotechnologies. Furthermore it could 
act as a model on which to build governance frameworks for other key emerging technologies 
(KETs). Therefore, in order to spur discussion about such a comprehensive NM risk 
governance framework and to suggest some key features and tools, we proffer a tentative 
version of such a framework in the following. 
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3. A FRAMEWORK FOR NM RISK GOVERNANCE 
3.1. The Essential Elements of the NM Risk Governance Framework 
We propose that to construct an effective risk governance framework for NMs, three element 
groups are required (see Figure 1): 
1. A set of advanced tools and strategies to support risk decision making. These start 
with assessment of the needs of the users (where do they work, what experience do 
they have in risk decision making, etc.) in order to ensure that the information 
provided is appropriate in content, style and level of detail.
(24)
 This assessment of user 
needs will be linked to tools for risk assessment (spanning hazard, exposure and 
physicochemical characterization), mitigation (e.g. prevention of exposure, or reduced 
hazard using Safer by Design approaches) and transfer (e.g. insurance), which all feed 
into a tool for risk decision making.
(25)
 The tools and strategies, which address 
potential risks posed by NMs along their value chain/life cycle, are currently both 
experimental and computational (see Table I, and Figure 1, central multi-colored 
circle). In line with ITS-NANO,
(26)
 we propose that the reliance on testing should 
decrease over time as computational models become more comprehensive and robust. 
2. An integrated model of human behavior and decision making (based on empirical data 
gathered at the individual, organizational, national and international level) that 
influences how the framework is refined, used and interpreted (Figure 1, green circle).  
3. An integrated overview of nano-specific and general legal regulatory requirements, 
the options within which are informed by a series of interlinked decision-making 
points along the value chain and life cycle of NMs (Figure 1, grey boxes). Regulations 
evolve with time, and so the framework needs to be able to adapt to changes in the 
broader regulatory environment.
(27)
 Simultaneously, by demonstrating the need and/or 
ability to deal with NMs of high or unknown risk, the framework can guide 
development of NM-specific regulations.  
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 9
We believe that the integration of these three elements has the potential to generate a robust 
and encompassing risk governance framework for NMs, which fulfills the six criteria outlined 
below. 
3.2. Criteria for a Promising NM Risk Governance Framework 
The goal of achieving sustainable development for nanotechnologies – by instilling 
trust into NM innovation and avoiding piece-meal solutions to risk governance – forms the 
starting point for our risk governance framework. Criteria for such a NM risk governance 
framework therefore include: 
The need to fully leverage existing knowledge and tools. A risk governance framework 
is most likely to further trust in NM innovation when integrating and exploiting the best, 
currently available tools (see Table I). Projects such as caLIBRAte (European Commission 
funded via Horizon 2020) are already working towards the calibration of such tools, and aim 
to collect and analyze existing control banding tools and quantitative hazard, exposure and 
risk assessment models and risk management systems for nanomaterials. Further, these tools 
are selected for sensitivity analysis, performance testing, further improvement and calibration 
with a final aim that the framework and its underlying tools represent the state of the art in 
analytical capacity to inform nanotechnology risk governance decision making. 
Robust protocols to address incomplete knowledge. Risk assessment, notably for next 
generation NMs, is likely to be based on incomplete datasets and subject to high uncertainty. 
Therefore, a framework which employs effective strategies to deal with gaps in knowledge is 
required.  
Ability to adapt to new insights and new NMs. Given the high velocity of 
developments in the NM field, static frameworks risk falling out of sync quickly. Therefore, a 
framework must be sufficiently adaptable as to allow the included tools to be updated for 
future generations of NMs, and to incorporate learning over time. Such an adaptive style of 
governance should be flexible enough to account for the unique political and institutional 
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 10
realities of a given jurisdiction, and allow existing regulatory structures to iteratively 
incorporate new risk knowledge over time such as via TSCA in the United States, or REACH 
regulations in the European Union.
(28)
 
Comprehensive consideration of the motivation of various users: For a framework to 
be effective, it has to accommodate the responses of the various parties (e.g., employers, 
workers, regulators, policy makers, insurers, general public) in order to motivate compliance 
and best practices. Motivations can be provided in a variety of forms, e.g., as financial 
incentives, as legal liabilities, socially embedded norms of appropriateness, role models or via 
a corporate code of conduct.  
Communicate the advantages of employing rules and regulations. For the rules and 
regulations to be effective, their rationale has to be effectively linked to the motivations, 
norms and interests of the various actors. This requires evidence and storylines of how they 
help in protecting workers, society, the environment and consequently the sustainability of 
nano industries.  
Delivering compliance and beyond: A risk governance framework for NMs seems 
most promising in achieving the objective of sustainable NMs if it not only fosters 
organizational practices which ensure compliance with current and future legal and regulatory 
requirements, but also goes beyond pure compliance and stimulates proactive ‘good’ behavior 
and innovation. 
By adopting these objectives the resultant risk governance framework will be 
responsive, rational, transparent and inclusive in the sense that it uses and constantly up-dates 
all available data, links them to decision-making guidance through publicly available rules 
and integrates the needs and concerns of a wide range of stakeholders.  
3.3. Tools and strategies for assessing potential risk and risk decision making 
We propose a set of four advanced tools and strategies to support risk decision making: risk 
banding, risk mitigation, risk transfer, and user capacities and needs. The first tool, risk 
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 11
banding,  stems from risk assessment strategies. Risk assessment systematically applies 
scientific principles, guided by the precautionary principle, to estimate the probability that 
adverse human health or environmental effects could emerge from exposure to substances. 
The risk assessment framework is composed of problem formulation, exposure assessment, 
hazard assessment as well as risk and uncertainty characterization.
(29)
 
The paradigm for risk assessment of chemicals is considered applicable to nanoscale 
materials,
(26,30,31)
 however many of the tools, test protocols and guidelines for determination 
and assessment of physicochemical properties, fate, exposure, and effects used for 
conventional chemicals need modifications when applied to (the regulatory) safety assessment 
of NMs. The work on adapting existing methods for NMs has been ongoing in the 
Organisation for Economic Co-operation and Development (OECD) Working Party of 
Manufactured Nanomaterials (WPMN) and in many research projects. This work has resulted 
in an array of nano-specific or nano-relevant experimental and modelling tools suited to 
address the complexity associated with the identity, biological and environmental interactions 
of NMs in order to reduce the uncertainty in their risk assessment. These tools were 
comprehensively reviewed by Hristozov et al.
(32)
 
These tools have been applied to generate extensive physicochemical, hazard and 
exposure datasets. However, while a significant body of data exists for some NMs, for many 
(including next-generation) NMs, risk assessment is likely to be based on incomplete datasets. 
When combined with the significant uncertainty regarding extrapolation from animal or in 
vitro hazard data to the quantification of human health or environmental risks, this lack of 
data could result in an under-protective or overly conservative assessment of health risks, 
resulting in either unacceptable risks or stifled innovation. Given the fast development of 
highly innovative NMs, it is not feasible to complete a risk assessment of NMs on a case-by-
case basis. Hence, new approaches to risk assessment are required
(33)
 which allow for 
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 12
accelerating the risk assessment process, for example via grouping and/or read-across of 
NMs.  
 Bodies such as the OECD and ECHA
(34-36)
 are developing NM grouping or 
categorization schemes
(37) 
in order to reduce the extensive hazard, exposure and 
physicochemical testing requirements to a feasible level. A number of studies have been 
developing risk banding tools (e.g., Stoffenmanager Nano,
(38)
 NanoRiskCat,
(39) 
Swiss 
Precautionary Matrix, NanoSafer etc), which are based on the Precautionary Principle and are 
designed to incorporate the full range of uncertainty in their results in order to inform risk 
management decisions based on worst-case scenarios.
(40)
 In a differing approach, the US 
FDA, among other agencies, convene quarterly interest groups which review risk and 
regulatory concerns of emerging trends in NM development, including risk categorization 
exercises and product-specific regulatory discussion.
(21,22)
 Moreover, risk screening and 
ranking schemes based on weight of evidence approaches have been proposed, which 
explicitly estimated the uncertainty stemming from hazard and exposure assessments. 
Specifically, Hristozov et al.
(41)
 developed the first quantitative Multi-Criteria Decision 
Analysis (MCDA) methodology for human health hazard identification of NMs, which 
incorporated data quality evaluation of the available dataset, based on the criteria adequacy, 
reliability, statistical and toxicological significance.
(42)
 Moreover, a quantitative MCDA 
approach for prioritization of nano-specific exposure scenarios was proposed for occupational 
settings,
(43)
 and a quantitative MCDA methodology for human health risk ranking of NMs 
was developed.
(44)
 All three approaches quantified the uncertainty in the assessments by 
means of a Monte Carlo methodology. 
If successful, such grouping and categorization schemes provide the opportunity to fill 
missing data within groups of similar NMs using computational (in silico) techniques such as 
Quantitative Structure Activity Relationships for NMs (abbreviated as: nano-QSAR, QNAR, 
QNTR)
(45-47)
 or read-across between NMs, or between NMs and other substances.
(47) 
As a 
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result, time and cost of testing as well as the use of laboratory animals could be reduced. In 
fact, great progress in developing in silico methods for risk assessment of NMs has been made 
by several EU FP7 “modelling projects” (NanoPUZZLES, MODERN, ModENPTox, 
MembraneNanoPart, PreNanoTox). These projects have jointly proposed criteria important 
for appropriate quality validation of nano-QSAR models to be developed in future 
initiatives.
(48)
 
 For such risk assessment tools to be effective they will require a combination of 
analytical, computational toxicology, machine learning and Bayesian methods to unravel and 
clearly communicate the uncertainties in the results. The risk assessment tool will need to 
provide information that is applicable to occupational, consumer and environmental settings, 
addressing different life cycle stages of the NMs in order to address risks from the design and 
manufacture stages through to disposal and recycling. The risk assessment tool should take 
into account the level of human and environmental exposure and be sufficiently flexible to 
accommodate new and future generations of NMs, even when the available data on hazard, 
exposure and physicochemical characteristics is scarce or even lacking (perhaps by using 
expert judgment and weight of evidence methodology in a transparent manner). Any risk 
assessment tool will need to push beyond the state-of-the-art by addressing the uncharted 
issues of uncertainty related to NM risks. This is relevant for consideration of human health 
and environmental impact of NMs including susceptible group(s) in the general population 
and susceptible species in the environment, as well as the impact of NM accumulation in 
environmental hot spots. It also includes consideration of human behavioral uncertainties 
based on diverging risk perceptions, organizational routines, and social norms. 
 To allow for effective risk management of NMs, the risk assessment tool could be 
linked with tools for risk mitigation and risk transfer. A range of practical NM risk mitigation 
strategies are required to reduce or prevent risks posed by NMs. These include technical risk 
mitigation approaches (e.g., safer-by-design), safer manufacturing processes, safer handling 
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procedures, and improved exposure controls (e.g., high-efficiency filters). Currently, 
mitigation approaches, including methods and tools, have been or are being developed in EU 
FP7 funded projects such as SUN, SANOWORK, NANOMICEX, NANOVALID and 
GUIDEnano. Safer-by-design approaches are also the main research topics of NANoREG II 
and ProSAFE. Other initiatives to prevent or minimize risk include the development and 
application of the precautionary principle, as well as soft law initiatives to drive consideration 
of nanomaterial-derived product liability and insurance.
(49,50)
 Tools designed to apply the 
precautionary principle are mostly inspired by the selection of appropriate levels of 
engineering controls (e.g., engineering techniques and personal protective equipment)
(46)
 or 
green safer product design or process optimization (e.g., NIOSH’s prevention though design 
initiative).
(51)
 
 Risk mitigation strategies also include management support tools (e.g., technical 
training materials for stakeholders) designed to promote adherence to health and safety 
policies. Development of such tools could result in improved strategic and transparent 
identification of approaches to mitigate human and environmental risks associated with NMs.  
 A governance framework has to provide guidance for the options for a relevant 
selection of mitigation measures especially in relation to their effectiveness and the value or 
quality of information about their effectiveness. Together with the definition of technical 
indicators (which quantify conditions in which measures success or failure) this could also 
facilitate the risk transfer by impacting on the reduction of risk premiums by insurance 
companies (see below). 
 The available options for risk transfer frame the risk management process in relation 
to factors such as non-contractual and contractual liabilities (see below), (re)insurability of 
risks, and the ensuing distribution of legal and financial risks that influence decision making. 
Currently, there is no systematic approach to qualify and quantify NM risk with regard to 
insurance. At present, insurers implicitly assume nano-specific risk in their health-related or 
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general-purpose insurance policies,
(52,53) 
an approach they are uncomfortable with but do not 
have the knowledge to exclude in a competitive business. To achieve reliable risk transfer 
arrangements, tools and associated guidance are required that allow mathematical 
quantification of risks and risk categorization in a context of uncertainty. In addition, tools are 
needed that identify or develop legally reliable arrangements (see below) between relevant 
parties involved in the life cycle and value chains relevant to NMs. 
 In order for the risk assessment, mitigation and transfer tools to guide effective risk 
management and risk decision making, their activities and outputs need to be integrated. This 
can be achieved through development and use of a decision support system (DSS). Prototype 
risk assessment and DSSs for NM risk management have been developed in FP7 funded 
projects such as SUN and GUIDEnano. These tools are in their early stages of development, 
and are based on the exploitation of a relatively small number of NM product case studies. 
Hence, a substantial body of work is required to enhance their reliability and suitability for 
wider arrays of NMs and NM products (across their value chain/life cycle), exposure 
scenarios and for a broader set of stakeholders. To improve DSSs further, it will be useful in 
the future to integrate the risk management tools with a tool to assess the needs, values and 
capacities of a wide range of users. The design of such a DSS allows the individual tools to be 
modified and advanced as each is improved, thereby ensuring that it remains up to date and 
relevant. Achievement of such a DSS optimally increases the efficiency of the risk 
governance process, for example by reducing the requirement for testing, and assists 
stakeholders with practical guidance in their decision making process for NMs throughout the 
value chain and life cycle.  
 For the governance framework to be useful for stakeholders it is essential that the 
outputs can be adjusted to meet the needs of the user and to provide a level of detail that is 
relevant to their understanding and expertise.
(54)
 Assessment of user capacities (e.g., 
experience and relevant knowledge) allows consideration of different types and levels of 
Page 15 of 28 Risk Analysis
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
 
 16
expertise (e.g., a ‘coal face’ worker never involved in risk assessment compared to an 
experienced occupational health professional).
(55)
 According to this type of analysis the 
framework and tools can be adapted to provide outputs that better suit the requirements and 
understanding of different types of users. 
 Finally, the DSS outputs need to integrate stakeholder values with evidence-based 
input in order to recommend clear actions for decision makers. Practical and clear advice for 
regulatory compliance and best practice should be provided (see below). Integration of these 
tools allows a national, international and potentially globally applicable standard for the 
governance of current and future NMs and their applications to be identified.  
3.4. Human behavior and decision making  
Human behavior and how individuals or organizations prepare and take decisions can vary 
considerably. Variability in decision making is driven via a wide array of factors including the 
social context in which the decision is made (e.g., domestic vs. occupational settings), the 
perception of risks versus potential benefits, the individual or organizational routines and 
heuristics (i.e. using decisional shortcuts with potential for error).
(56,57)
 These factors apply 
whether the decision is made by an individual or a team, and whether it is made to align with 
specific regulations, guidelines or ethical considerations.  
 To generate an effective governance framework, there is a need to identify the 
individual, organizational and societal determinants of decision making about NM risk 
management and transfer along the full value chain and life cycle of NMs. While generic 
analytical frameworks are available to identify such determinants (e.g., the homo 
oeconomicus institutionalis framework
(58)
), determinants are expected to vary across different 
types of contexts. Hence inputs from stakeholders and the wider public are needed to identify 
how user concerns and needs depend on the types of decisions (e.g., NM design, which NM to 
use, how to dispose of a NM) and the type of contexts (e.g., research laboratory, factory, or in 
a regulatory capacity). Building on such context-specific insights will allow for developing 
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differentiated risk communication strategies, which need to be dialogical (two-way), to enable 
co-learning and to enhance trust in the governance of risks from NMs.  
4. IMPLEMENTATION OF THE RISK GOVERNANCE FRAMEWORK 
Before such a framework can be delivered the individual tools need to be generated and 
validated. The tool development will need to be evidence-based taking into account the norms 
and motivations of the users and the impediments to be addressed by the governance 
framework. The tools need to be built on existing achievements of on-going or completed 
national or international projects, going beyond the state-of-the-art by systematically 
diagnosing user needs and capacities, integrating likely behavior, dynamic links to developing 
knowledge about NM risks, integration of uncertainty into risk assessment. Importantly, to 
achieve this they need to undergo interactive testing in practice.
(59)
 Empirical studies will 
therefore be required to illustrate how the tools and guidance of the framework function in a 
comprehensive and relevant range of practice contexts, and to verify its reliability. Case 
studies which do not focus on various NMs in isolation, but rather a range of NMs along their 
respective value chains and life cycles, including interactions with people in different settings 
(e.g., in industries, as regulators, as researchers, as consumers and in the environment), seem 
a promising way to gain these insights. Such case studies would need to include a breadth of 
natural and social science data. Ideally, each case study would demonstrate how an open 
society addresses the issue of emerging technology and its possible inherent risks in a 
responsible manner. This will include arrangements for the transfer of risks and the steps 
required by insurers before underwriting any risks. It will also include signposts for 
communicating the risks, in creating a narrative that informs and involves the stakeholders in 
making the key governance decisions to help nurture and sustain the nano industries in a 
socially desirable manner. 
 We believe that an international strategy to build such a governance framework is 
necessary in order to ensure that the framework is sufficiently adaptable to allow and 
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encourage improved national, international and global harmonization as well as sustain and 
likely expand the global market for nanotechnology. Such a framework needs also to 
empower the broad range of stakeholders in nanotechnology governance with tools that 
improve practical decision-making in a governance framework that is perceived by society as 
fair, trustworthy and effective. Furthermore it provides a vehicle to share and organize 
information, thereby improving the efficiency of risk decision-making.
(60)
 
5. FUTURE STEPS  
With this article, we would like to call for an international strategy to develop an integrated 
risk governance framework for NMs. This would enable a cooperative and international 
approach to the governance of NM-related risks through the systematic consideration and 
integration of stakeholder and user needs, dynamic risk assessment tools and consideration of 
the various regulatory requirements in multi-layered and fragmented regulatory environments. 
For rendering such an effort successful, the essential elements of the framework need to be 
delivered and integrated effectively. The outlined strategy will support stakeholders with 
diverse backgrounds and knowledge requirements, essentially providing a ‘user paradigm’ 
consisting of practical advice and solutions for existing and innovative NMs entering the 
market. Continued involvement of all relevant stakeholders throughout the construction of the 
framework will be essential. This inclusive approach guarantees the maximal stakeholder 
involvement through construction, consultation, and revision phases. Furthermore, the 
strategy involves the stakeholders in the design, testing and implementation of the framework 
and this process of co-production thereby safeguards its relevance and transparency leading 
to enhanced potential for trust.
(61)
  
 In achieving this risk governance strategy, new solutions will be provided to evaluate 
the risks potentially arising from the use of NMs, including future NMs. In this regard, the 
governance framework will likely have significant impact on nanotechnology industries and 
for investors in nanotechnology, supporting SMEs and large companies in the selection of 
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safer products and processes, limiting the potential adverse effects of NMs on workers and 
consumers, and reducing insurance costs and risks to public budgets derived from any 
potential future major accidents or diseases.
(62)
  
By enabling the emergence of reliable expectations about the behaviors and decisions 
along the value chain, the governance framework proposed here would be attractive for key 
stakeholders, including the insurance industry which underwrites the risks of these 
technologies, and the financial industry which invests in it. It would facilitate coordinated risk 
assessment, management and communication across diverging regulatory environments. 
Achievement of such a governance framework will help to realize informed, effective, 
responsive and proportionate governance of NM risks for humans and the environment. It is 
thus a cornerstone for optimizing social and economic benefits of nanotechnology.  
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Table I. 
Definitions for risk management tools 
Tool Definition 
Risk banding 
Allows risk assessment to be performed with 
incomplete hazard, exposure and 
physicochemical characterization  
Risk mitigation 
Provides advice on technical interventions that 
can reduce the risk and supports 
worker/decision-making training 
Risk transfer 
Enables consideration of legal, contractual and 
insurance arrangements to be made in the 
decision-making process 
User needs and capacities 
Assesses expertise and experience of user to 
determine the format of the information required 
and the level of detail 
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Figure 1.  
Essential elements for a risk governance framework for nanomaterials. The central circle 
houses tools that feed into a decision support system. The decisions generated are guided by 
the legal/regulatory frameworks (grey boxes), which are determined and interpreted by 
humans in real life situations (green circle). 
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